Advancing neoadjuvant therapies in resectable non-small cell lung cancer: implications for novel treatment strategies and biomarker discovery
The delivery of neoadjuvant and perioperative therapies for non-small cell lung cancer has been radically altered by significant advances and by the incorporation of targeted therapies as well as immune checkpoint inhibitors alone or alongside conventional chemotherapy. This evolution has been parti...
Saved in:
Main Authors: | Hyein Jeon (Author), Rajvi Gor (Author), Angelica D'Aiello (Author), Brendon Stiles (Author), Peter B. Illei (Author), Balazs Halmos (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer
by: Ivy Riano, et al.
Published: (2023) -
Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series
by: Yan Hu, et al.
Published: (2022) -
Evidence for the evolving role of neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancer
by: Thomas Hansen, et al.
Published: (2024) -
Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives
by: Luis A. Godoy, et al.
Published: (2023) -
Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future considerations
by: Wenliang Liu, et al.
Published: (2022)